Impact Assessment of Active Trachoma Control in Garki Local Government Area of Jigawa State, Nigeria

J. A. Ogungbenjo

Paediatrics and Strabismus Department, National Eye Centre, Kaduna State, Nigeria.

L. A. Raji

Department of Cornea and Anterior Segment, National Eye Centre, Kaduna, Nigeria.

D. Musa *

Department of Community Ophthalmology, Research and Data Management Unit, National Eye Centre, Kaduna, Nigeria.

A. Hassan

Paediatrics and Strabismus Department, National Eye Centre, Kaduna State, Nigeria.

M. B. Alhassan

Department of Vitreoretinal, National Eye Centre, Kaduna, Nigeria.

*Author to whom correspondence should be addressed.


Background: An estimated prevalence of trachoma inflammation – follicular (TF) of 20.9% was reported in Garki local government area (LGA). This led to annual mass azithromycin administration for three years targeted at eliminating TF in the LGA. This study was conducted to assess the impact of the mass azithromycin administration on prevalence of active trachoma in Garki LGA of Jigawa State, Nigeria.

Methods: A population-based cross-sectional survey of children aged 1- 9 years was conducted in April 2015. The study size was empowered at the sub-district level as recommended by a WHO-led scientific meeting. Subjects were selected using a two-stage cluster randomized sampling at sub-district level. A total of 1,746 children were targeted to be examined in each of the 4 sub-districts of the LGA. Each study participant was assessed for trachomatous inflammation - follicular (TF) and trachomatous trichiasis (TT). The households were also interviewed and/or assessed on              access to water, hygiene and sanitation. All findings were recorded into the data collection proforma.

Results: A response rate of 92.6% (n = 6,472) was obtained in the whole LGA and it ranged between 92.2% and 93% across the 4 sub-districts. The mean age of participants was 3.8 years (SD 2.47). The prevalence of TF was 13.6% (95% CI 12.8% – 14.5%) for the LGA and ranged between 9.2% to 16.5% across the sub-districts. The prevalence of TT was 0.1% (95% CI: 0.09% - 0.12%). Presence of active trachoma was significantly associated with dirty faces, presence of human feaces and animal dung around the house at p < 0.05.

Conclusion: Active trachoma is still hyperendemic in Garki Local Government Area of Jigawa State. There is need to undertake annual mass azithromycin distribution for additional 3 years before another impact assessment.

Keywords: Trachoma, azithromycin, TF, TT, TI, CO, ITI, CBM

How to Cite

Ogungbenjo, J. A., Raji, L. A., Musa, D., Hassan, A., & Alhassan, M. B. (2022). Impact Assessment of Active Trachoma Control in Garki Local Government Area of Jigawa State, Nigeria. Asian Journal of Research and Reports in Ophthalmology, 5(1), 117–127. Retrieved from


Download data is not yet available.


Sandford-Smith J. Eye Diseases in Hot Climates. Oxford Butterworth-Heinemann. 1997;120-159.

West SK. Blinding trachoma: Prevention with the safe strategy. Am J Trop Med Hyg. 2003;69(Suppl 5):18-23.

Manson-Bahr PEC, Bell DR. Manson’s Tropical Diseases, London Baillière Tindall. 19th Edition. 1987;1142-1145.

Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63-70.

Mariotti SP. Global data on visual impairments 2010 (WH0/NMH/PBD/12.01). Geneva: World Health Organization; 2012.

Foster A, Gilbert C, Johnson G. Changing patterns in global blindness: 1988-2008 Community Eye Health. 2008;21(67):37-39.

Tailor HR. Trachoma: A blinding scourge from the bronze age to the twenty-first century. Melbourne, Australia: Haddington Press. 2008;10-49

Jones BR. “The prevention of blindness from trachoma.” Transactions of the Ophthalmological Society of the United Kingdom. The Bowman Lecture. 1975; 95:16-32.

Tower P. The History of trachoma. Archives of Ophthalmology.1963;69:157-164.

Albert DM, Edwards DD. The history of ophthalmology. Cambridge, MA: Blackwell Science. 1996;18-192.

Al-Rifai, Ikassim MJ. Trachoma through history. International Ophthalmology. 1988;12(1):9-14.

Arrington, George(jr) E A. History of Ophthalmology. New York: MD Publications, Inc. 1959;55-119.

WHO. Trachoma control: A guide for program managers. Geneva, World Health Organization. 2006;4-49.

Federal Minisry of Health Abuja. Zithromax application in Nigeria- revised post GTMP. 2014;1-6

Ministry of Health, Jigawa State. Jigawa State Eye Care Plan for 2009 – 2013;2-7

Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. Nov. 2004;82(11):844-852.

Ramyil A, Wade P, Ogoshi C, Goyol M, Adenuga O, Dami N, et al. Prevalence of Trachoma in Jigawa State, Northwestern Nigeria. Ophthalmic Epidemiology. 2015;22(3):184-189.

Mpyet C. Report of CBM Vision 2020 support programme sponsored trachoma prevalence survey. Ministry of Health, Jigawa State; 2008.

Muhammad N, Mohammed A, Isiyaku S, Adamu MD, Gwom A, Rabiu MM. Mapping Trachoma in 25 local government areas of Sokoto and Kebbi States, Northwest Nigeria. The Br J Ophthalmol. 2013;98: 432- 437.

Mpyet C, Lass BD, Yahaya HB, Solomon AW. Prevalence of and risk factors for trachoma in Kano state, Nigeria. PLoS one. 2012;7(7):e40421.

Muhammad N, Damina M, Umar MM, Isiyaku S. Trachoma prevalence and risk factors in eight local government areas of Zamfara State. Niger J Ophthalmol. 2015;23:48-53.

Jip NF, King JD, Diallo MO, Miri ES, Hamza AT, Ngondi J, et al. Blinding trachoma in Katsina State, Nigeria: Population-based prevalence survey in ten local government areas. Ophthalmic Epidemiology. 2008;15(5):294-302.

Bamani S, King JD, Dembele M, Coulibaly F, Sankara D, Kamissoko Y, et al. Where do we go from here? prevalence of trachoma three years after stopping mass distribution of antibiotics in the regions of Kayes and Koulikoro, Mali. PLoS Neglected Tropical Diseases. 2010;4(7): e734.

Hagan M, Yayemain D, Ahorsu F, Aboe A. Prevalence of active trachoma two years after control activities. Ghana Med J. 2009;43(2):54-60.

Hagi M, Schemann JF, Mauny F, Momo G, Sacko D, Traore L, et al. Active trachoma among children in mali: Clustering and environmental risk factors. PLoS Neglected Tropical Diseases. 2010;4(1):e583.

Mpyet C, Ogoshi C, Goyol M. Prevalence of trachoma in Yobe State, North-Eastern Nigeria. Ophthalmic Epidemiology. 2008; 15(5):303-307.

Ramesh A, Kovats S, Haslam D, Schmidt E, Gilbert CE. The impact of climatic risk factors on the prevalence, distribution, and severity of acute and chronic trachoma. PLoS Neglected Tropical Diseases. 2013;7(11):e2513.

King JD, Odermatt P, Utzinger J, Ngondi J, Bamani S, Kamissoko Y, et al. Trachoma among children in community surveys from four African countries and implications of using school surveys for evaluating prevalence. Int Health. 2013;5(4):280- 287.

Fraser-Hurt N, Bailey RL, Cousens S, Mabey D, Faal H, Mabey DCW. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ. 2001;79(7):632-640.

Harding-Esch EM, Edwards T, Sillah A, Sarr-Sissoho I, Aryee EA, Snell P, et al. Risk factors for active trachoma in The Gambia. Trans R Soc Trop Med Hyg. 2008;102(12):e1016.

West SK, Bailey R, Munoz B, Edwards T, Mkocha H, Gaydos C, et al. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. PLoS Neglected Tropical Diseases. 2013;7(8):e2415.

Harding-Esch EM, Edwards T, Mkocha H, Munoz B, Holland MJ, Burr SE, et al. Trachoma prevalence and associated risk factors in the gambia and tanzania: Baseline results of a cluster randomised controlled trial. PLoS Neglected Tropical Diseases. 2010;4(11):e861.

Ssemanda EN, Munoz B, Harding-Esch EM, Edwards T, Mkocha H, Bailey RL, et al. Mass treatment with azithromycin for trachoma control: Participation clusters in households. PLoS Neglected Tropical Diseases. 2010;4(10):e838.

Wikipedia. List of African countries by population. Assessed on 17th May. 2014.


Stalker P. Oxford university press: A guide to countries of the world; New York: Oxford university press; 2010.

Assessed on 17th May 2014.


Huguet P, Bella L, Einterz EM, Goldschmidt P, Bensaid P. Mass treatment of trachoma with azithromycin 1.5% eye drops in the republic of cameroon: Feasibility, tolerance and effectiveness. Br J Ophthalmol. 2010;94(2):157-160.

Kalua K, Chirwa T, Kalilani L, Abbenyi S, Mukaka M, Bailey R. Prevalence and risk factors for trachoma in central and southern Malawi. PLoS One. 2010; 5(2):e9067.

Yohannan J, Munoz B, Mkocha H, Gaydos CA, Bailey R, Lietman TA, et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma: PRET ziada trial results. JAMA Ophthalmology. 2013;131 (4):431-436.

Tellis B, Fotis K, Keeffe JE, Taylor HR. Trachoma surveillance annual report 2008: A report by the national trachoma surveillance and reporting Unit; 2009.

Cromwell EA, King JD, McPherson S, Jip FN, Patterson AE, Mosher AW, et al. Monitoring of mass distribution interventions for trachoma in Plateau State, Nigeria. PLoS neglected tropical diseases. 2013;7(1):e1995.

Vashist P, Gupta N, Rathore AS, Shah A, Singh S. Rapid assessment of trachoma in underserved population of car-nicobar island, India. PLoS One. 2013;8(6): e65918.

DOI: 10.1371/journal.pone.0065918.

Schémann JF, Sacko D, Malvy M, Momo G, Taore L, Bore O, et al. Risk factors for trachoma in Mali. Int. J Epidemiol. 2002; 31:194-201.

Zack R, Mkocha H, Zack E, Munoz B, West SK. Issues in defining and measuring facial cleanliness for national trachoma control programs. Trans R Soc Trop Med Hyg. 2008;102:426- 431.

Tailor HR, West SK, Mmbaga BBO, Katala SJ, Turner V, Lynch M, et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch Ophthalmol. 1989; 107:1821-1825